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Abstract
The interaction among multiple genes and environmental factors can affect an individual’s
susceptibility to disease. Some genes may not show strong marginal associations when they affect
disease risk through interactions with other genes. As a result, these genes may not be identified by
single-marker methods that are widely used in genome-wide association studies. To explore this
possibility in real data, we carried out a two-stage model selection procedure of joint single-
nucleotide polymorphism (SNP) analysis to detect genes associated with rheumatoid arthritis (RA)
using Genetic Analysis Workshop 16 genome-wide association study data. In the first stage, the
genetic markers were screened through an exhaustive two-dimensional search, through which
promising SNP and SNP pairs were identified. Then, LASSO was used to choose putative SNPs
from the candidates identified in the first stage. We then use the RA data collected by the
Wellcome Trust Case Control Consortium to validate the putative genetic factors. Balancing
computational load and statistical power, this method detects joint effects that may fail to emerge
from single-marker analysis. Based on our proposed approach, we not only replicated the
identification of important RA risk genes, but also found novel genes and their epistatic effects on
RA. To our knowledge, this is the first two-dimensional scan based analysis for a real genome-wide
association study.
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In the past several years, genome-wide association
studies (GWAS) have achieved great successes in
identifying hundreds of genetic variants that affect
dozens of complex diseases. Most studies reported to
date primarily employed a single-marker-based analysis
strategy. As multiple genetic variations and environ-
mental risk factors are expected to jointly affect a
complex phenotype, it is natural to ask whether there
is any benefit from conducting a joint marker analysis,
e.g., a systematic study of all possible pairwise interac-
tions, versus single-marker analysis [1]. Both simulations
[2,3] and analytical studies [4] indicate that an exhaus-
tive two-dimensional (2-D) scan may have higher
statistical power under certain genetic models, e.g.,
when certain epistatic effects exist. It is important to
find whether real GWAS data have such epistatic patterns
favoring a 2-D scan. To answer this question, we
conducted a 2-D scan for a GWAS data set from the
North American Rheumatoid Arthritis Consortium
(NARAC) supplied by Genetic Analysis Workshop 16
(GAW16). We studied the extra information offered by
2-D scan and identified epistatic effects. Furthermore, we
propose a two-stage analysis strategy that incorporates
single-marker analysis, 2-D scan, and a multiple marker
analysis using LASSO to balance statistical power and
computational feasibility in GWAS analysis.
Methods
In the first stage of our proposed method for joint
marker analysis, single-nucleotide polymorphisms
(SNPs) are screened by using both a marginal search
(single-marker analysis) and 2-D scan. For the marginal
search, the simple logistic regression model is employed
for each SNP j as follows:
logit(disease probability) ~ . αα 01 jj j X + (1)
The 2-D scan evaluates all possible SNP pairs by using
the following additive models and interaction models:
logit(disease probability) ~ , αα α 01 2 jk jk j jk k XX ++
(2)
logit(disease probability) ~ ′ + ′ + ′ + ′ αα α α 01 2 3 jk jk j jk k jk j k XXX X , ,
(3)
where 1 ≤ j ≤ k ≤ p index SNPs, genotype values Xj and
Xk = 0, 1, or 2 denote the number of the minor allele at
each SNP. The overall statistical significance of Models
(1), (2), and (3) measures the significance of the marginal
effect of SNP j,t h eadditive joint effects of SNPs j and k,a n d
the complete joint effects of SNPs j and k, respectively.
In Model (2), the statistical significance of parameters
a1jk (or a2jk)m e a s u r e st h econditional additive effects of
SNP j (or k), given SNP k (or j). In Model (3), the
significance of ′ α3jk measures the interaction effect
(epistasis) between SNPs j and k.T h ec o r r e s p o n d i n g
log-likelihood-ratio test statistics (LLR) quantify the
statistical significance of models and parameters and
thus the corresponding genetic effects. We wrote a
C-program to implement logistic regression analysis,
allowing for the exhaustive 2-D search (this program is
available upon request from the authors). We chose the
SNPs from the models that were ranked highest based
on LLR.
After the first stage analysis identifies a set of candidate
SNPs and SNP interactions, we apply the LASSO model
selection method [5,6] to select predictive factors from
those candidates.
In the LASSO model, the variables to be considered are
either genotype values that reveal signals of marginal
and conditional additive effects, or the products of
genotype values, i.e., interaction terms, which reveal the
signals of epistases. We use the R package glmnet [7] for
the logistic regression model selection.
Results
Data cleaning
For GAW16 data quality control, we excluded those
SNPs whose Hardy-Weinberg equilibrium p-values <
0.001 or minor allele frequencies < 0.01, and also
excluded SNPs or individuals with missing rates >10%.
Outliers were removed based on principal component
analysis. Consequently, the final data include 500,884
SNPs and 2,002 individuals (862 cases and 1,140
controls). In the first-stage analysis the missing observa-
tions of the corresponding SNP(s) were eliminated at
each model fitting. In the second stage, we imputed the
missing SNP genotypes using software Beagle [8].
First stage
Marginal association in Model (1)
There are 395 SNPs showing significant marginal effects
with LLR > 27.04 (Bonferroni p-values < 0.1). Most of
these SNPs are located in chromosome region 6p21, with
high linkage disequilibrium (LD) existing among some
of them. We sorted the test statistics of marginal
association in decreasing order. The blue solid curve in
Figure 1 exhibits the LLR values for these 395 SNPs. The
green dot curve shows the top marginal LLRs without the
SNPs in chromosome 6 (chr6), which contains the most
signals for rheumatoid arthritis (RA) as reported in the
literature. As a reference baseline, the red dash curve
shows the top 395 values from the marginal LLRs of all
SNPs when the disease status is permuted, i.e., when no
association exists between RA and any SNP in the whole
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dash curve, it suggests that additional marginal associa-
tion signals exist outside of chr6.
Conditional additive effect in Model (2)
Because a two-marker model can be statistically sig-
nificant if one of the SNPs has an extremely high
marginal association, we did not study the conditional
additive effects of the top 200 marginally associated
SNPs (LLR > 49) in Model (2). Excluding these 200
SNPs, 71,693 two-marker full models in Form (3) (with
18,391 unique SNPs) were found to be significant with
LLR > 59.37 (Bonferroni p-value < 0.1). Hierarchically
nested within these full models, 70,795 two-marker
additive models in Form (2) contain at least one SNP
with a conditional additive effect that has an LLR > 27.04
(Bonferroni p-value < 0.1). These additive models
involve 18,388 unique SNPs, 11.46% of which are on
chr6.
A SNP can show a significant conditional additive effect
given many other different SNPs. To avoid duplications,
we included only one SNP pair that has the targeted SNP
showing significant conditional additive effect. We
obtained 494 pairs of SNPs that consisted of 506 unique
SNPs (75.3% are from chr6, 505 have significant
conditional additive effect). To illustrate the connection
between conditional additive effects and marginal
effects, Figure 2 shows the log-transformed marginal
association ranks of the two SNPs in each pair. Almost
all of the SNP-pairs include at least one SNP with
relatively large marginal effect indicated by lower
marginal ranks. This fact implies the existence of two
possible situations: a SNP with large marginal effect may
also exert a large conditional additive effect; or, a SNP
with a small marginal effect can contribute a significant
additive association given another SNP that has a large
marginal effect. To check the prevalence of the second
situation in our analysis, 33 of the 505 conditionally
significant SNPs actually show small marginal effect
(with LLRs for single-marker model <10, or the marginal
ranks >4300).
To illustrate the LD pattern of the SNP pairs that have
large conditional additive effects, Figure 3 shows the
histogram of D’ of the chosen 494 SNP-pairs. Most of the
SNP-pairs have relatively strong LD (60.73% have D’ >
0.2, by the R package genetics [9]). In particular, for the
above-mentioned 33 SNP pairs containing SNPs with
small marginal but large conditional effects, their LDs
are all significant (D’ > 0.39). Because this LD pattern
indicates that these SNP pairs are physically spaced
closely, their significant conditional additive effects may
represent haplotype effects.
Figure 1
Top log-likelihood test statistics for the marginal
models. Blue solid curve shows the 395 top values of
marginal LLR from original data; the green dot curve shows
the top marginal LLR excluding the SNPs in chr6; the red
dash curve shows the top marginal 395 LLRs from all SNPs
after permuting RA disease status.
Figure 2
Log marginal association ranks for SNP pairs with
significant conditional additive effect.E a c hd o t
represents a SNP pair (totally 494 SNP-pairs). Displacement
of a dot along the x- and y-axes indicate the log of the
marginal association ranks for the corresponding two SNPs.
A lower marginal rank indicates a larger marginal effect.
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Epistasis is another type of joint effect, which is
represented by the interaction term in Model (3). The
top 208 epistatic terms have their corresponding LLRs >
40, or unadjusted p-values < 2.54 × 10
-10. Of these 208
interactions, 46 are significant (LLR > 52.78; Bonferroni
p-values < 0.047. In Figure 4, the blue solid curve
shows the values of these 208 LLR in decreasing order.
Among these 208 epistatic terms, 160 (or 196) terms
(as illustrated in the green dot curve) involve the SNP
pairs that either exist in different chromosomes or have
D’ < 0.2 (or 0.4). The red dash curve represents 208 top
LLR values measuring the best interaction terms in the
null scenario that is obtained from fitting all SNP pairs
to a permuted RA status. The difference between the red
d a s hc u r v ea n dt h eb l u es o l i dc u r v ei n d i c a t e st h e
presence of epistasis. Because the green dot curve has
excluded the pairs of SNPs likely located in the regions
of strong LD, the closeness between the blue solid and
g r e e nd o tc u r v e ss u g g e s t st h a tm o s to ft h e s ei d e n t i f i e d
epistatic effects are not likely due to haplotype effects.
This means that even though these interactive SNPs are
mostly located within a chromosome (84.6% are in
chr6), haplotype analysis has limited power to find
these epistatic effects discovered through an exhaustive
2-D search. For these top 208 epistatic pairs, Figure 5
demonstrates the log-transformed ranks of their mar-
ginal effects, and shows that many SNPs have strong
interactions but small marginal effects. Following this,
we expect that genome-wise 2-D screening may be
more informative than the marginal single-marker
screening.
Second stage
The goal of the second stage is to jointly select from the
candidates: first, the top 395 SNPs with significant
marginal associations in Model (1); second, the 506
unique SNPs from the 494 SNP pairs with significant
conditional additive effects in model (2); and third, the
top 208 epistatic SNP pairs by Model (3). In total, 914
variables were selected as input variables for LASSO
selection, in which 706 variables were the genotypes of
non-overlapping SNPs; 208 variables were the cross-
products of genotype values of the 208 SNP-pairs.
To obtain a model that associates RA disease status with
SNPs [7]. Bayesian information criterion (BIC) was used
as the criterion to choose the tuning parameter l.T h e
LASSO model selection generated 63 non-zero coeffi-
cients, all for the SNPs from Models (1) and (2). LASSO
did not pick up any interactions that represent epistasis.
The result (available upon request) contains genes
reported in the literature where marginal association
Figure 3
Histograms of D’ of SNP pairs with significant
conditional additive effect. Bars show the distribution of
the number of SNP-pairs (totally 494 SNP pairs) over the
values of D’.Al a r g eD ’ indicates significant linkage
disequilibrium between two SNPs.
Figure 4
Top log-likelihood test statistics for the large
interaction effects. The blue solid curve shows the top
208 decreasingly ordered LLR test statistics, among which
160 values corresponds to SNP-pairs that exist on different
chromosomes or have D’ < 0.2, as represented by the green
dot curve. The red dash curve shows the top 208 LLR test
statistics for the interaction terms after a permutation of the
disease status.
BMC Proceedings 2009, 3(Suppl 7):S29 http://www.biomedcentral.com/1753-6561/3/S7/S29
P a g e4o f7
(page number not for citation purposes)studies were applied, i.e., PTPN22 (rs2476601), HLA
genes, and C5 (rs2900180) [10-13]. Furthermore, it also
includes many genes showing relatively small marginal
association but significant joint effects when studied
together with the other genes.
Validation
Validate the two-stage method selection with WTCCC data
Using the Wellcome Trust Case Control Consortium
(WTCCC) data [11], we sought to validate the genes
indentified in the two-stage method with the GAW16
data. SNPs in the GAW16 data were mapped to genes
through the SNP annotation file provided by Plenge et
a l .[ 1 2 ] .T h eg e n e sw e r et h e na s s o c i a t e dw i t hW T C C C
SNPs based on the gene information downloaded from
NCBI [14]. Fifty-seven genes were located by the 63
selected GAW16 SNPs showing large marginal or
conditional additive effects. However, the two genes
LOC389362 and C14orf151 (and their aliases) among
those 57 genes are not represented in the WTCCC data.
Within the rest of genes (or around ± 5 kbp if no SNP is
found within the gene), we retrieved WTCCC SNPs.
Again, missing genotypes were imputed by Beagle [8].
We got 1,371 WTCCC SNPs from the 61 genes. Their
genotypes were fed as candidates into the LASSO model
selection. The number of SNPs selected by LASSO
depends on the value of tuning parameter l.I no r d e r
to guarantee that the LASSO-selected SNPs are statisti-
cally significant as a whole set, we chose the value of l
that led to the average number of false positive
predictors to be less than 0.05 under the null hypothesis
of no association. Specifically, with the selected value of
l, we permuted the responses for 1,000 times and
obtained an average model size of 0.05. Table 1
summarizes the jointly selected genetic factors associated
with RA by LASSO. Large marginal ranks of some
identified SNPs indicate the single-marker analysis
cannot find these SNPs at a reasonable significant
level. Corresponding to these found SNPs, gene
PTPN22 and the major histocompatability complex
(MHC) region genes HLA and BTNL2 reported in the
literature are also contained in our results. Gene C6orf10
is located in the MHC region, but to the best of our
knowledge was not previously reported as RA risk genes.
Associated genes PGCP and MYO18B are in novel regions
on 8q22.2 and 22q11.1, respectively.
Validation for pair-wise epistases with WTCCC data
We tried to validate the 103 gene-gene interactions
(involving 91 unique genes) which were identified by
the 208 most significant SNP pair epistases detected with
Model (3) in the first stage of GAW16 data analysis. The
WTCCC data were used to check whether significant
epistases exist between SNPs from the corresponding
gene pairs. Applying the same data quality control
procedures as for GAW16 data, 1,781 unique SNPs
were extracted from the WTCCC data and combined into
35,515 SNP-pairs according to the corresponding gene-
pairs. Table 2 lists the validated significant gene-gene
interactions (Bonferroni p-value < 0.05). These results
show that the important gene-gene interactions for RA
interactions are mostly located within the MHC region,
but may reflect redundant information about the over-
lapped regions.
Discussion
Joint SNP analysis can benefit GWAS more than single-
SNP analysis in at least two aspects. First, in GWAS many
strong marginal associations are likely due to strong LD
with a truly associated locus. So single-marker analysis
may pick up many SNPs but mostly they are nested
within one or two narrow genomic regions. In joint
analysis, e.g., LASSO selection, SNPs that have high
correlation with those already included in the model are
less likely to be added into the model again. This may
help us to study more interesting regions while keeping
in mind the hotspots. In other words, if we retain the
Figure 5
Marginal association ranks of SNP pairs with large
interaction effects. Each dot represents a SNP pair (totally
208 SNP pairs). Displacement of a dot along the x- and
y-axes indicate the log of the marginal association ranks for
the corresponding two SNPs.
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analysis likely brings a wider genome region into further
consideration. Second, joint analysis can identify truly
associated predictors that have small marginal signals
but large conditional additive effects or large epistatic
effects. Empirical data suggest this scenario does exist.
These findings are potentially valuable in further
exploring the relationships among genes in pathway
studies.
T w oi m p o r t a n ti s s u e ss h o u l db en o t e dw i t hr e g a r dt oo u r
methodology. First, LASSO tends to over-fit when
choosing l based on the BIC criterion. To illustrate this
issue does exist, we permuted the disease status of the
WTCCC data set in the validation stage, in which the
BIC-controlled LASSO led to false-positive selection. To
overcome this problem, permutation was used to
determine an appropriate value for l when quantifying
the proportion of false positives. Second, in the second
stage of selection, it may cause over-fit when isolated
applying the significance control to the SNPs identified
by screening the same data set. To prove this problem
exists, we permuted the RA status before going through
the whole two-stage analysis procedure for the GAW16
data set. In this case, even though no SNP is associated
with the disease, LASSO still selected some variables,
even if a l value was chosen in the second stage in the
same way as we did for WTCCC validation. To address
this problem, we may similarly apply the same proce-
dure using permutations at the outset of screening
Table 1: WTCCC-data-validated SNPs and SNP pairs (epistases) associated with RA





1 rs3811019 114183625 PTPN22 0 1.46 6.93 × 10
-7 1150
6 rs1265777 32381136 C6orf10 0 1.01 9.84 × 10
-1 436
6 rs574710 32396168 C6orf10 0 0.89 7.44 × 10
-1 488
6 rs539703 32396440 C6orf10 0 1.05 9.34 × 10
-1 440
6 rs2894249 32433813 C6orf10 0 0.79 3.76 × 10
-4 245
6 rs2076533 32471505 BTNL2 0 2.03 2.00 × 10
-16 630
6 rs3763308 32482618 BTNL2 0 0.42 1.91 × 10
-8 959
6 rs9268645 32516505 HLA-DRA 0 0.85 2.90 × 10
-2 278
6 rs7194 32520458 HLA-DRA 0 1.02 7.96 × 10
-1 110
6 rs9273363 32734250 HLA-DQB1 5 0.73 4.14 × 10
-9 709
6 rs6908943 32743274 HLA-DQB1 5 0.69 2.92 × 10
-7 1131
8 SNP_A-4193342 97922693 PGCP 0 1.38 1.68 × 10
-7 416671
22 rs16981203 24729414 MYO18B 0 1.3 1.08 × 10
-5 501
a± kbp, location of the SNPs. “0” indicates the SNP is physically located within the corresponding gene; “5” i n d i c a t e st h eS N Pi sl o c a t e do u t s i d et h e
gene but is less than 5 kbp away.
bOR, the joint odds ratios and p-values in the full model containing all of the selected variables.
cp-value, for the full model containing all of the selected variables.
dMarg. Rank, marginal ranks of the SNPs by single-marker analysis in the WTCCC data. The rank >1015 corresponds to the Bonferroni p-value > 0.1
in a single-marker study.
Table 2: SNP-pairs with large epistatic effects validated with WTCCC data
Chr1 SNP1 Location1 Gene1 Marg. Rank1
a Chr1 SNP1 Location1 Gene1 Marg. Rank2
a p-Value
6 rs2244579 31544618 HCP5 2933 6 rs206015 32290737 NOTCH4 623 1.39 × 10
-5
6 rs4394275 31426156 HLA-B 4705 6 rs9276440 32822761 HLA-DQA2 3042 5.33 × 10
-5
6 rs4394275 31426156 HLA-B 4705 6 rs9276432 32820362 HLA-DQA2 2165 1.06 × 10
-4
6 rs4394275 31426156 HLA-B 4705 6 rs9276429 32820082 HLA-DQA2 2386 1.08 × 10
-4
6 rs2248880 31341489 HLA-C 130792 6 rs9273363 32734250 HLA-DQB1 709 1.14 × 10
-4
6 rs4394275 31426156 HLA-B 4705 6 rs9276431 32820225 HLA-DQA2 2484 1.40 × 10
-4
6 rs9263794 31237998 TCF19 4325 6 rs438475 32294223 NOTCH4 1243 7.56 × 10
-4
6 rs1265074 31221193 CCHCR1 20388 6 rs438475 32294223 NOTCH4 1243 2.20 × 10
-3
6 rs2244579 31544618 HCP5 2933 6 rs438475 32294223 NOTCH4 1243 2.27 × 10
-3
6 rs4394275 31426156 HLA-B 4705 6 rs9273363 32734250 HLA-DQB1 709 3.49 × 10
-3
6 rs2844615 31350938 HLA-C 10590 6 rs2596477 31435702 HLA-B 76640 2.36 × 10
-2
6 rs4394275 31426156 HLA-B 4705 6 rs2227127 32819760 HLA-DQA2 585 3.16 × 10
-2
6 rs2736172 31698877 BAT2 406 6 rs438475 32294223 NOTCH4 1243 3.37 × 10
-2
6 rs1063635 31487910 MICA 897 6 rs206015 32290737 NOTCH4 623 3.41 × 10
-2
Each row gives the annotations of SNP-pairs with validated epistatic effects.
aMarg. Rank 1 and 2 give the ranks of single-marker association strengths of the SNPs 1 and 2 in the WTCCC data. The rank > 1015 corresponds to
the Bonferroni p-value > 0.1 in a single-marker study.
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data. However, this requires intensive computation and
may lead to fewer SNPs to be followed up in other
studies. In practice, these issues can be alleviated by
using a separate data set to validate the results. In this
w a yw ec a nc a r r yo u tas c r e e n i n ga n dt h e na p p l yL A S S O ,
while properly controlling l for the final model in the
validation stage.
We reported our results using a Bonferroni p-values at
t h e0 . 1l e v e li nt h ef i r s ts t a g eb e c a u s ew ew o u l dl i k et o
avoid missing true associations, and hope that the
s e c o n ds t a g ea n a l y s i sw i l lb ea b l et os e l e c tt e r m s
according to a more stringent criterion. We have also
tried the significance control level of 0.05 that led to
slightly fewer gene findings (except obtaining one extra
gene C14orf151) from the GAW16 data analysis. How-
ever, both control levels led to exactly the same set of
detected signals shown in Table 1, after the validation
procedure with the WTCCC data. Therefore, our method
seems to be robust to the choice of the threshold levels
in this range.
Conclusion
In GWAS, there exist SNPs with small marginal but large
joint associations with RA. To extract more information
from GWAS data, we have proposed a two-stage
association detection method based on an exhaustive
two-dimensional screening and the LASSO model selec-
tion. Our method studies joint associations including
gene-gene interactions. Applying this joint analysis
method to GAW16 data and validating the results with
a separate data set (WTCCC data), we have found novel
genes associated with RA, as well as interactions
implying complex RA associations in the MHC region.
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